close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Medical History

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Medical History

Review your patient’s information.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Olatunji B. Alese

location-icon

Atlanta, GA

LOCATION OF PRACTICE
Emory Healthcare
MEDICAL Specialty:

Gastric Cancer



NPI Number
1053631010
ABOUT

Olatunji B. Alese, MD is an oncologist specializing in the treatment of gastrointestinal cancers, particularly colorectal cancer. Dr. Alese also serves as an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and is the director of gastrointestinal oncology at Winship Cancer Institute of Emory University.

Dr. Olatunji B. Alese profile image

Published Articles

Morphine-induced hepatotoxicity in rats: Sex and dose variations in liver enzymes, oxidative stress, inflammation, apoptosis, and histopathology.- 2026 May 28
Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.- 2026 May 1
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.- 2026 Apr
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.- 2026 Apr
Gut Microbiome and Psychoneurological Symptoms Among Patients With Colorectal Cancer and Their Caregivers: A Pilot Study.- 2026 Apr 24
Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.- 2026 Apr
Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.- 2026 May 12
Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.- 2026 Apr 10
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.- 2026 Jan
A phase Ib/II trial of XL888 (HSP90 inhibitor) and pembrolizumab in metastatic pancreatic cancer with translational immune profiling.- 2026 Feb 28

Clinical Trials

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

My Patient Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider